Gilead Sciences, Inc. (Nasdaq:GILD):
-- Total Revenues of $685.3 Million, Up 38 Percent over Second
Quarter 2005
-- Record Product Sales of $590.7 Million, Up 32 Percent over
Second Quarter 2005
-- EPS of $0.56 per Share, Up 34 Percent over Second Quarter 2005
Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of
operations for the quarter ended June 30, 2006. Total revenues for the
second quarter of 2006 were $685.3 million, up 38 percent compared to
total revenues of $495.3 million for the second quarter of 2005. Net
income for the second quarter of 2006 was $265.2 million, or $0.56 per
diluted share, which included after-tax stock-based compensation
expense of $27.7 million from the impact of the adoption of the
Financial Accounting Standards Board's Statement No. 123 (revised
2004), "Share Based Payment" (SFAS 123(R)) on January 1, 2006.
Excluding after-tax stock-based compensation expense, non-GAAP net
income for the second quarter of 2006 was $292.9 million, or $0.61 per
diluted share. Net income for the second quarter of 2005 was $196.0
million, or $0.41 per diluted share.
Product Sales
Product sales were a record $590.7 million for the second quarter
of 2006, marking eleven consecutive quarters of product sales growth.
This growth continues to be driven primarily by Gilead's HIV product
franchise, including the continued robust performance of Truvada(R)
(emtricitabine and tenofovir disoproxil fumarate), as well as
continued strong product sales for Hepsera(R) (adefovir dipivoxil).
HIV Franchise
HIV product sales were $475.4 million in the second quarter of
2006, a 38 percent increase from $344.4 million for the same period in
2005.
-- Truvada
Truvada sales were $299.3 million for the second quarter of 2006,
an increase of 143 percent from Truvada sales in the second quarter of
2005. Sales of Truvada commenced in the United States in the third
quarter of 2004 and in the major markets of the European Union during
2005. Truvada sales accounted for more than 60 percent of Gilead's
total HIV product sales in the second quarter of 2006.
-- Viread
Sales of Viread(R) (tenofovir disoproxil fumarate) were $167.4
million in the second quarter of 2006, a 20 percent decrease from
$209.1 million in the second quarter of 2005. Viread sales volume has
decreased across major geographical regions due primarily to patients
switching from a Viread-containing regimen to one containing Truvada
in countries where Truvada is available.
-- Emtriva
Emtriva(R) (emtricitabine) sales were $8.7 million for the second
quarter of 2006, down 29 percent from the second quarter of 2005. This
decrease is primarily driven by patients switching from an
Emtriva-containing regimen to one containing Truvada in countries
where Truvada is available.
AmBisome for Severe Fungal Infections
AmBisome sales for the second quarter of 2006 were $55.6 million,
a decrease of one percent compared to the second quarter of 2005. This
is primarily due to slightly lower sales volume and pricing in Europe,
offset by higher sales volume in Asia and Latin America.
Hepsera for Chronic Hepatitis B
Sales of Hepsera totaled $56.8 million for the second quarter of
2006, a 24 percent increase from $45.8 million in the second quarter
of 2005. The increase in sales for the second quarter of 2006 was
primarily driven by volume growth in both the United States and
Europe.
Royalty and Contract Revenues
For the second quarter of 2006, royalty and contract revenues
resulting from collaborations with corporate partners totaled $94.6
million, an increase of $47.8 million from the second quarter of 2005.
The increase in the second quarter of 2006 was primarily driven by the
recognition of Tamiflu(R) (oseltamivir phosphate) royalties from F.
Hoffmann-La Roche Ltd (Roche) of $73.3 million. This amount was
significantly higher than the Tamiflu royalties of $36.2 million
recognized in the second quarter of 2005. The increase was primarily
due to the significantly higher Tamiflu sales recorded by Roche during
the first quarter of 2006 compared to the same period in 2005, as well
as the elimination of a contractual cost of goods adjustment that had
historically reduced the amount of Tamiflu royalties recognized by
Gilead.
"We are pleased to have achieved a very solid second quarter in
2006, including total revenues of $685 million," said John F.
Milligan, Ph.D., Executive Vice President and Chief Financial Officer
of Gilead. "Our year-to-date revenues from total product sales have
exceeded a record $1 billion. Gilead's strong sales are, in part, a
result of the growth rates seen in the European markets where we hit a
major milestone in the second quarter of this year with nearly $250
million in European product sales. This is a very exciting time for
the company as we continue to make great strides in accomplishing our
goals for the year."
Research and Development
Research and development (R&D) expenses for the second quarter of
2006 were $90.5 million, which included stock-based compensation
expense of $12.9 million, compared to R&D expenses of $59.7 million
for the same quarter in 2005. R&D expenses for the second quarter of
2006 were higher due to increased headcount, increased clinical,
product development and research activities with our hepatitis C,
hepatitis B and HIV programs, as well as stock-based compensation
expense from Gilead's adoption of SFAS 123(R).
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses for the second
quarter of 2006 were $151.6 million, which included stock-based
compensation expense of $21.3 million, compared to SG&A expenses of
$94.8 million for the same quarter in 2005. The higher SG&A expenses
in the second quarter of 2006 compared to the second quarter of 2005
were primarily due to increased headcount and expenses driven by our
significant business growth and business development activities,
preparation for new product launches, as well as stock-based
compensation expense from Gilead's adoption of SFAS 123(R).
Cash, Cash Equivalents and Marketable Securities
As of June 30, 2006, Gilead had cash, cash equivalents, and
marketable securities of $3.30 billion. This compared to $2.31 billion
as of December 31, 2005. The increase in cash, cash equivalents and
marketable securities was primarily attributable to $487.8 million of
operating cash flows generated during the first six months of 2006 and
$587.6 million of net proceeds generated from our issuance of
convertible senior notes and related transactions, partially offset by
$101.0 million paid towards principal on our term loan.
Other Balance Sheet Highlights
Inventories increased by $101.8 million from December 31, 2005 to
$318.7 million as of June 30, 2006, primarily driven by the impending
launch of the co-formulation of Truvada and Bristol-Myers Squibb
Company's (BMS') Sustiva(R) (efavirenz), and the related purchases of
Sustiva active pharmaceutical ingredient from BMS at BMS' approximate
market value of Sustiva.
Corporate Highlights
In April 2006, Gilead announced an investment of $25.0 million in
Corus Pharma, Inc., a privately-held Seattle-based company focused on
the development of novel drugs for respiratory diseases. In return for
the investment, Gilead received preferred shares in Corus and became
the second largest shareholder in the company. In connection with the
investment, Gilead also received an exclusive option to purchase the
remaining shares of Corus at a pre-specified price. On July 19, 2006,
Gilead announced that it has agreed to exercise its option to purchase
Corus for $365.0 million. The option exercise will be effective within
10 business days from announcement. The companies expect the deal to
close in the third quarter of 2006, subject to clearance under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other closing
conditions. Concurrently, Gilead and Novartis Vaccines and
Diagnostics, inc. have entered into an agreement whereby Novartis has
agreed to dismiss the ongoing litigation with Corus for an undisclosed
payment.
In April 2006, Gilead announced the closing of its sale of $1.30
billion principal amount of convertible senior notes to institutional
buyers pursuant to Rule 144A under the Securities Act of 1933, as
amended. Contemporaneously, Gilead also purchased convertible note
hedges at a cost of $379.1 million, sold warrants for net proceeds of
$235.5 million in private transactions and repurchased $544.9 million
(8.4 million shares) of its common stock under its stock repurchase
program.
In May 2006, Gilead announced that the company is offering
non-exclusive licenses for the manufacturing of tenofovir DF to
generic manufacturers in India for the local Indian market and for
export to the 97 developing world countries included in Gilead's
Access Program.
In May 2006, Gilead announced that Judge Martin J. Jenkins of the
United States District Court for the Northern District of California
dismissed with prejudice the securities class action complaint, In re
Gilead Sciences Securities Litigation, Case No. C03-4999 MJJ, filed in
2003 against Gilead and certain of its current and former officers.
The plaintiffs have appealed the dismissal.
In June 2006, Gilead announced that the company signed a
definitive agreement under which Gilead plans to acquire Canadian
subsidiary Raylo Chemicals Inc. from Germany-based, specialty
chemicals company Degussa AG. Under the terms of the agreement, which
is subject to certain closing conditions, Gilead will pay
approximately 115.2 million Euros (approximately $144.3 million) to
Degussa. In addition, Gilead has entered into long-term agreements
with Degussa for the supply of raw materials and the manufacture of
certain active pharmaceutical ingredients for Gilead products. The
companies expect the transaction to close in the fourth quarter of
2006.
Product and Pipeline Highlights
"The second quarter of 2006 marked the achievement of several
important milestones and continued progress against our goal of
delivering new therapies to patients and physicians," said John C.
Martin, Ph.D., President and Chief Executive Officer of Gilead.
"Together with our partner Bristol-Myers Squibb, we filed our New Drug
Application (NDA) with the U.S. Food and Drug Administration (FDA) for
the co-formulation of Truvada and Sustiva in late April of this year.
On July 12, 2006, just two and a half months after the filing, we
received approval for this novel drug, which has been given the trade
name ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir
disoproxil fumarate 300 mg). ATRIPLA now offers patients and
physicians the first-ever once-daily single tablet regimen for HIV. We
were able to ship to our wholesalers within 24 hours of FDA approval,
and we are very pleased to report that the first prescriptions for
ATRIPLA were filled just this past Friday."
Dr. Martin continued, "In addition, we continued to advance our
other pipeline products. During the second quarter, we completed
enrollment in the two Phase III studies evaluating tenofovir DF for
the potential treatment of chronic hepatitis B. Our novel oral HIV
integrase inhibitor, GS 9137, is also progressing on schedule, with
enrollment now complete in our Phase II study."
Conference Call
At 4:30 p.m. Eastern Time today, Gilead will webcast a conference
call live on Gilead's website to discuss its second quarter 2006
results. During the call, Gilead will be discussing additional
corporate, financial, statistical, product and pipeline information.
That information can be found on Gilead's website at www.gilead.com
under "Investors." To access the webcast via the internet, log on to
www.gilead.com. Please connect to the company's website at least 15
minutes prior to the conference call to ensure adequate time for any
software download that may be needed to hear the webcast.
Alternatively, please call 1-800-561-2718 (U.S.) or 1-617-614-3525
(international) and dial the participant passcode 46618905 to access
the call. Telephone replay is available approximately two hours after
the call through July 23, 2006. To access, please call 1-888-286-8010
(U.S.) or 1-617-801-6888 (international) and dial the participant
passcode 67884555. The webcast will be archived on www.gilead.com for
one year.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet
medical need. The company's mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America,
Europe and Australia.
Non-GAAP Financial Information
Non-GAAP financial information is utilized by Gilead management to
better understand the comparative operating performance of the
company.
Forward-looking Statements
Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
include those relating to: revenues, R&D expenses, and SG&A expenses;
the efficacy of any marketed or pipeline products; the timing of and
ability to obtain marketing approval for Gilead's development
products; or the market introduction, competitive positioning and
commercial arrangements for sale of its marketed or pipeline
development products. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could
cause actual results to differ materially. These risks and
uncertainties include our ability and the ability of our partners to
introduce and market our products and grow revenues successfully, in
particular, our ability to sustain the uptake and revenues for our HIV
franchise; our ability to accurately estimate end-user demand since we
must make numerous assumptions and must rely on incomplete data to
make these estimates; our ability to effectively manage wholesaler
inventory levels and the impact of those efforts on revenues; our
ability to generate additional positive clinical data, including with
respect to tenofovir DF and GS 9137, and expand the labels for our
existing products; our ability to control the timing and amount of
spending in our research and clinical programs; our ability to protect
our patents and other intellectual property both domestically and
internationally; competition, legislation or regulations affecting
product pricing, reimbursement or access; unanticipated expenses such
as litigation or legal settlement expenses; fluctuations in foreign
currency against the U.S. dollar; our ability to continue to observe
the safety, tolerability and efficacy data for our products that we
have observed to date as the safety and efficacy data obtained in
controlled clinical trials for such products may not be observed in an
uncontrolled clinical setting; the reluctance of physicians to
prescribe Truvada or ATRIPLA if they fail to see advantages of these
products over other antiretrovirals; the unpredictable variability of
Tamiflu royalties and the strong relationship between this revenue and
global pandemic planning and supply; our ability to consummate the
purchase of Corus Pharma, Inc. as the transaction is subject to
closing conditions, including the expiration or termination of the
applicable Hart-Scott-Rodino Antitrust Improvements Act waiting
period, and our ability to successfully integrate the business, if and
when, the transaction is consummated; our ability to satisfy the
closing conditions and consummate the purchase of Raylo Chemicals Inc.
from Degussa AG, and other risks identified from time to time in
Gilead's reports filed with the U.S. Securities and Exchange
Commission. You are urged to consider statements that include the
words "may," "will," "would," "could," "should," "might," "believes,"
"estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed," "goal,"
or the negative of those words or other comparable words to be
uncertain and forward-looking.
Gilead directs readers to its Annual Report on Form 10-K for the
year ended December 31, 2005, its Quarterly Report on Form 10-Q for
the first quarter of 2006 and its subsequent current reports on Form
8-K. Gilead claims the protection of the Safe Harbor contained in the
Private Securities Litigation Reform Act of 1995 for forward-looking
statements. All forward-looking statements are based on information
currently available to Gilead, and Gilead assumes no obligation to
update any such forward-looking statements.
Viread, Emtriva, Truvada, AmBisome and Hepsera are registered
trademarks of Gilead Sciences, Inc.
ATRIPLA is a trademark of Bristol-Myers Squibb & Gilead Sciences,
LLC.
Tamiflu is a registered trademark of F. Hoffmann-La Roche Ltd.
Sustiva is a registered trademark of Bristol-Myers Squibb Company.
For more information on Gilead Sciences, please visit
www.gilead.com or call the Gilead Public Affairs Department at
1-800-GILEAD-5 (1-800-445-3235).
-0-
*T
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(unaudited)
(in thousands, except per share amounts)
Three months ended Six months ended
June 30, June 30,
--------------------- ----------------------
2006 2005 2006 2005
---------- --------- ---------- ---------
Revenues:
Product sales $ 590,691 $ 448,458 $1,150,044 $ 848,669
Royalty and contract
revenues 94,611 46,811 228,136 77,014
---------- ---------- ----------- ----------
Total revenues 685,302 495,269 1,378,180 925,683
Costs and expenses:
Cost of goods sold
(1)(3) 77,883 63,269 168,240 120,684
Research and
development (1) 90,536 59,697 178,936 130,131
Selling, general and
administrative
(1)(4) 151,568 94,805 294,037 173,893
---------- ---------- ----------- ----------
Total costs and expenses 319,987 217,771 641,213 424,708
---------- ---------- ----------- ----------
Income from operations 365,315 277,498 736,967 500,975
Interest and other
income, net (4) 37,360 9,787 65,885 17,106
Interest expense (5,207) (15) (8,931) (24)
Minority interest in
joint venture 1,244 914 2,238 1,175
---------- ---------- ----------- ----------
Income before provision
for income taxes 398,712 288,184 796,159 519,232
Provision for income
taxes (1) 133,562 92,217 268,305 166,152
---------- ---------- ----------- ----------
Net income $ 265,150 $ 195,967 $ 527,854 $ 353,080
========== ========== =========== ==========
Net income per share -
basic $ 0.58 $ 0.43 $ 1.15 $ 0.78
========== ========== =========== ==========
Net income per share -
diluted (1) $ 0.56 $ 0.41 $ 1.10 $ 0.75
========== ========== =========== ==========
Shares used in per share
calculation - basic 457,505 452,942 459,454 451,255
========== ========== =========== ==========
Shares used in per share
calculation - diluted
(2) 476,217 472,595 479,004 470,226
========== ========== =========== ==========
------
Notes:
(1) On January 1, 2006, we adopted SFAS 123(R) and recorded stock-
based compensation expense during the three and six months
ended June 30, 2006. The following is a reconciliation of our
GAAP and non-GAAP net income:
Three months ended Six months ended
June 30, 2006 June 30, 2006
------------------ ----------------
Net income (GAAP) $ 265,150 $ 527,854
Stock-based
compensation expense:
Cost of goods sold 2,526 5,713
Research and
development
expenses 12,892 24,842
Selling, general
and administrative
expenses 21,349 35,845
Provision for income taxes (9,046) (15,175)
---------- ----------
Total stock-based
compensation expense,
net of taxes 27,721 51,225
---------- ----------
Net income excluding after-tax
stock-based compensation expense
(Non-GAAP) $ 292,871 $ 579,079
========== ==========
Shares used in per share
calculation - diluted (Non-GAAP)
(2) 476,746 479,757
========== ==========
Net income per share - diluted,
excluding after-tax stock-based
compensation expense (Non-GAAP) $ 0.61 $ 1.21
========== ==========
(2) Shares used in the calculation of GAAP and non-GAAP net income
per diluted share for the three months ended June 30, 2006
include the effect of outstanding stock options to purchase 18.7
million and 19.2 million shares of common stock, respectively,
applying the treasury stock method with and without stock-based
compensation expense.
Shares used in the calculation of GAAP and non-GAAP net income
per diluted share for the six months ended June 30, 2006 include
the effect of outstanding stock options to purchase 19.5 million
and 20.3 million shares of common stock, respectively, applying
the treasury stock method with and without stock-based
compensation expense.
(3) For the six months ended June 30, 2006, cost of goods sold
includes $6.8 million recorded in the first quarter of 2006 to
decrease the book value of inventory for our Access Program to
reflect its net realizable value.
(4) Certain prior period amounts have been reclassified to be
consistent with current period presentation.
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
June 30, December 31,
2006 2005
------------- -------------
(unaudited) (Note 1)
Cash, cash equivalents and
marketable securities (2) $3,299,666 $2,311,033
Other current assets (2) 1,004,286 781,175
Property, plant and equipment, net 253,760 242,568
Other noncurrent assets 620,638 429,875
------------- -------------
Total assets $5,178,350 $3,764,651
============= =============
Current liabilities (2) $507,968 $465,163
Long-term liabilities (2) 1,472,468 271,710
Stockholders' equity 3,197,914 3,027,778
------------- -------------
Total liabilities and
stockholders' equity $5,178,350 $3,764,651
============= =============
Note:
(1) Derived from audited consolidated financial statements at that
date.
(2) Certain prior period amounts have been reclassified to be
consistent with current period presentation.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
(in thousands)
Three months ended Six months ended
June 30, June 30,
------------------------ -----------------------
2006 2005 2006 2005
----------- ----------- ----------- ----------
HIV products:
Truvada - U.S. $ 207,738 $ 111,731 $ 387,528 $ 200,439
Truvada -
International 91,517 11,379 160,673 13,838
----------- ----------- ----------- -----------
299,255 123,110 548,201 214,277
Viread - U.S. 74,802 88,430 150,644 184,945
Viread -
International 92,639 120,681 208,573 222,009
----------- ----------- ---------- -----------
167,441 209,111 359,217 406,954
Emtriva - U.S. 4,314 4,898 8,320 10,312
Emtriva -
International 4,351 7,235 10,307 14,267
----------- ----------- ----------- -----------
8,665 12,133 18,627 24,579
Total HIV products
- U.S. 286,854 205,059 546,492 395,696
Total HIV products
- International 188,507 139,295 379,553 250,114
----------- ----------- ----------- -----------
475,361 344,354 926,045 645,810
Hepsera - U.S. 23,800 19,116 46,189 37,438
Hepsera -
International 33,044 26,689 63,310 51,032
----------- ----------- ----------- -----------
56,844 45,805 109,499 88,470
AmBisome 55,628 56,207 109,428 110,421
Other products 2,858 2,092 5,072 3,968
----------- ----------- ----------- -----------
Total product
sales $ 590,691 $ 448,458 $1,150,044 $ 848,669
=========== =========== =========== ===========
*T
